```
 * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:48:53 ON 25 SEP 2011

=> file biosis medline caplus wpids uspatfull
COST IN U.S. DOLLARS                                 SINCE FILE      TOTAL
                                                        ENTRY    SESSION
FULL ESTIMATED COST                                      0.23       0.23

FILE 'BIOSIS' ENTERED AT 15:49:38 ON 25 SEP 2011
Copyright (c) 2011 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 15:49:38 ON 25 SEP 2011

FILE 'CAPLUS' ENTERED AT 15:49:38 ON 25 SEP 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2011 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 15:49:38 ON 25 SEP 2011
COPYRIGHT (C) 2011 THOMSON REUTERS

FILE 'USPATFULL' ENTERED AT 15:49:38 ON 25 SEP 2011
CA INDEXING COPYRIGHT (C) 2011 AMERICAN CHEMICAL SOCIETY (ACS)

*** YOU HAVE NEW MAIL ***

=> s label? (4a) target
L1       29662 LABEL? (4A) TARGET

=> s l1 and linker (4a) peptide (7a) bond
L2         144 L1 AND LINKER (4A) PEPTIDE (7A) BOND

=> s l2 and linker (4a) consecutive (4a) peptide bonds
L3           0 L2 AND LINKER (4A) CONSECUTIVE (4A) PEPTIDE BONDS

=>  s l1 and linker (4a) consecutive (4a) peptide bonds
L4           0 L1 AND LINKER (4A) CONSECUTIVE (4A) PEPTIDE BONDS

=> s l2 and linker (4a)(amino acid or aliphatic chain or alkene or alkyne or ring
or sugar)
   3 FILES SEARCHED...
L5          88 L2 AND LINKER (4A)(AMINO ACID OR ALIPHATIC CHAIN OR ALKENE OR
               ALKYNE OR RING OR SUGAR)

=> s l5 and 2002/py
L6           4 L5 AND 2002/PY

=> dup rem l6
PROCESSING COMPLETED FOR L6
L7           4 DUP REM L6 (0 DUPLICATES REMOVED)

=> d l7 bib abs 1-4

L7   ANSWER 1 OF 4  USPATFULL on STN
AN     2002:272801  USPATFULL
TI     Compositions and methods for the therapy and diagnosis of colon cancer
IN     Stolk, John A., Bothell, WA, UNITED STATES
       Xu, Jiangchun, Bellevue, WA, UNITED STATES
       Chenault, Ruth A., Seattle, WA, UNITED STATES
       Meagher, Madeleine Joy, Seattle, WA, UNITED STATES
```

PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 20020150922 A1 20021017 <--
AI US 2001-998598 A1 20011116 (9)
PRAI US 2001-304037P 20010710 (60)
US 2001-279670P 20010328 (60)
US 2001-267011P 20010206 (60)
US 2000-252222P 20001120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 9233
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 2 OF 4 USPATFULL on STN
AN 2002:243051 USPATFULL
TI Compositions and methods for the therapy and diagnosis of ovarian cancer
IN Algate, Paul A., Issaquah, WA, UNITED STATES
Jones, Robert, Seattle, WA, UNITED STATES
Harlocker, Susan L., Seattle, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 20020132237 A1 20020919 <--
AI US 2001-867701 A1 20010529 (9)
PRAI US 2000-207484P 20000526 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 25718
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 3 OF 4 USPATFULL on STN
AN 2002:242791 USPATFULL
TI Compositions and methods for the therapy and diagnosis of colon cancer
IN King, Gordon E., Shoreline, WA, UNITED STATES

Meagher, Madeleine Joy, Seattle, WA, UNITED STATES
Xu, Jiangchun, Bellevue, WA, UNITED STATES
Secrist, Heather, Seattle, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES (U.S. corporation)
PI US 20020131971 A1 20020919 <--
AI US 2001-33528 A1 20011226 (10)
RLI Continuation-in-part of Ser. No. US 2001-920300, filed on 31 Jul 2001, PENDING
PRAI US 2001-302051P 20010629 (60)
US 2001-279763P 20010328 (60)
US 2000-223283P 20000803 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8083
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 4 OF 4 USPATFULL on STN
AN 2002:148269 USPATFULL
TI Multivalent target binding protein
IN Leung, Shui-on, Shatin, HONG KONG
PI US 20020076406 A1 20020620 <--
AI US 2001-911610 A1 20010725 (9)
PRAI US 2000-220782P 20000725 (60)
DT Utility
FS APPLICATION
LREP FOLEY & LARDNER, Washington Harbour, Suite 500, 3000 K Street, N.W.,
Washington, DC, 20007-5109
CLMN Number of Claims: 41
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 1776
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A novel multivalent target binding protein which comprises a first and a second polypeptides and has at least three target binding sites is described. The first polypeptide of the multivalent target binding protein comprises a first scFv molecule and a first immunoglobulin-like domain which preferably comprises an immunoglobulin light chain variable region domain. The second polypeptide of the multivalent target binding protein comprises a second scFv molecule and a second immunoglobulin-like domain which preferably comprises an immunoglobulin heavy chain variable region domain. The first scFv molecule and the first immunoglobulin-like domain are preferably linked via a first extra amino acid sequence which preferably comprises an immunoglobulin light chain constant region domain. The second scFv molecule and the second immunoglobulin-like domain are preferably linked via a second extra

amino acid sequence which preferably comprises an immunoglobulin heavy chain constant region domain. The first and second extra amino acid sequences preferably associate with each other via at least one disulfide bond. The multivalent target binding protein of the present invention is useful for treating and detecting tumors and infectious lesions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
=> s l5 not l7
L8          84 L5 NOT L7

=> s l8 and 2002/pd
L9           0 L8 AND 2002/PD

=> d his

     (FILE 'HOME' ENTERED AT 15:48:53 ON 25 SEP 2011)

     FILE 'BIOSIS, MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 15:49:38 ON
     25 SEP 2011
L1        29662 S LABEL? (4A) TARGET
L2          144 S L1 AND LINKER (4A) PEPTIDE (7A) BOND
L3            0 S L2 AND LINKER (4A) CONSECUTIVE (4A) PEPTIDE BONDS
L4            0 S L1 AND LINKER (4A) CONSECUTIVE (4A) PEPTIDE BONDS
L5           88 S L2 AND LINKER (4A)(AMINO ACID OR ALIPHATIC CHAIN OR ALKENE O
L6            4 S L5 AND 2002/PY
L7            4 DUP REM L6 (0 DUPLICATES REMOVED)
L8           84 S L5 NOT L7
L9            0 S L8 AND 2002/PD

=> s l8 and 2004/py
L10           4 L8 AND 2004/PY

=> d l10 bib abs 1-4

L10  ANSWER 1 OF 4  USPATFULL on STN
AN     2004:64489  USPATFULL
TI     Templated molecules and methods for using such molecules
IN     Pedersen, Henrik, Bagsvaerd, DENMARK
       Gouilaev, Alex Haahr, Vesko Sjaelland, DENMARK
       Franch, Thomas, Odense C, DENMARK
       Sams, Christian Klarner, Frederiksberg C, DENMARK
       Olsen, Eva Kampmann, Herlev, DENMARK
       Slok, Frank Abilgaard, Kobenhavn N, DENMARK
       Husemoen, Gitte Nystrup, Kobenhavn N, DENMARK
       Felding, Jakob, Charlottenlund, DENMARK
       Hyldtoft, Lene, Virum, DENMARK
       Norregaard-Madsen, Mads, Birkerod, DENMARK
       Godskesen, Michael Anders, Vedbaek, DENMARK
       Glad, Sanne Schroder, Ballerup, DENMARK
       Thisted, Thomas, Frederikssund, DENMARK
       Freskgard, Per-Ola, Vellinge, SWEDEN
       Holtmann, Anette, Ballerup, DENMARK
PA     Nuevolution A/S, Copenhagen, DENMARK (non-U.S. corporation)
PI     US 20040049008      A1  20040311                              <--
       US 7727713          B2  20100601
AI     US 2002-175539      A1  20020620 (10)
PRAI   DK 2001-962             20010620
       US 2001-299443P         20010621 (60)
```

US 2002-364056P 20020315 (60)
DT Utility
FS APPLICATION
LREP BROWDY AND NEIMARK, P.L.L.C., 624 NINTH STREET, NW, SUITE 300, WASHINGTON, DC, 20001-5303
CLMN Number of Claims: 316
ECL Exemplary Claim: 1
DRWN 100 Drawing Page(s)
LN.CNT 11215
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a method for synthesising templated molecules. In one aspect of the invention, the templated molecules are linked to the template which templated the synthesis thereof. The intion allows the generation of libraries which can be screened for e.g. therapeutic activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 2 OF 4 USPATFULL on STN
AN 2004:57417 USPATFULL
TI Javelinization of protein antigens to heat shock proteins
IN Rothman, James E., New York, NY, UNITED STATES
Hoe, Mee H., Irvington, NY, UNITED STATES
Mayhew, Mark, New York, NY, UNITED STATES
PI US 20040043419 A1 20040304 <--
AI US 2003-258147 A1 20030813 (10)
WO 2001-US12567 20010417
DT Utility
FS APPLICATION
LREP KENYON & KENYON, ONE BROADWAY, NEW YORK, NY, 10004
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 1250
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to antigenic complexes, wherein an antigenic complex comprises a peptide or protein containing a plurality of epitopes non-covalently joined to a heat shock protein via a molecular tether referred to as a "javelin". Such complexes do not require that each epitope Be defined, and may in certain embodiments, elicit both antibody and cell-mediated immune reactions. The complexes of the invention may be used to induce therapeutic immune responses directed toward the treatment or prevention of infectious diseases and malignancies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 3 OF 4 USPATFULL on STN
AN 2004:25211 USPATFULL
TI Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
IN Roark, William Howard, Ann Arbor, MI, UNITED STATES
PI US 20040019053 A1 20040129 <--
AI US 2003-619662 A1 20030715 (10)
PRAI US 2002-396903P 20020717 (60)
DT Utility
FS APPLICATION
LREP WARNER-LAMBERT COMPANY, 2800 PLYMOUTH RD, ANN ARBOR, MI, 48105
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN No Drawings

LN.CNT 8040
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides a combination, comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof. This invention also provides a method of treating a disease that is responsive to inhibition of MMP-13 and cyclooxygenase-2, comprising administering to a patient suffering from such a disease the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof. This invention also provides a pharmaceutical composition, comprising the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient.

The invention combination may also be further combined with other pharmaceutical agents depending on the disease being treated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 4 OF 4 USPATFULL on STN
AN 2004:24365 USPATFULL
TI Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates
IN Pastan, Ira, Potomac, MD, UNITED STATES
Tsutsumi, Yasuo, Mino, JAPAN
Onda, Masanori, Rockville, MD, UNITED STATES
Nagata, Satoshi, Rockville, MD, UNITED STATES
Lee, Byungkook, Potomac, MD, UNITED STATES
Kreitman, Robert J., Potomac, MD, UNITED STATES
PI US 20040018203 A1 20040129 <--
AI US 2002-297337 A1 20021204 (10)
WO 2001-US18503 20010608
DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 2142
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to the site-specific PEGylation of immunoconjugates. In particular, the present invention provides immunoconjugates wherein a connector molecule attaching a targeting molecule to an effector molecule is conjugated to one or more polyethylene glycol molecules. The present invention further provides methods for increasing the antitumor activity of an immunotoxin, comprising attaching in a site-specific manner one or more polyethylene glycol molecules to a linker connecting a toxic moiety to a targeting moiety of an immunotoxin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s l8 and label?/ti

```
L11          1 L8 AND LABEL?/TI

=> d 111 bib abs

L11  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2011 ACS on STN
AN   2003:570953  CAPLUS
DN   139:113655
TI   Fluorescent serine protease affinity labeling agents and methods for
     determining apoptotic state of cells
IN   Phelps, David J.; Johnson, Gary L.; Lee, Brian W.; Darzynkiewicz,
     Zbigniew; Grabarek, Jerzy
PA   Immunochemistry Technologies, LLC, USA
SO   PCT Int. Appl., 53 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ----------------    ----   --------    ---------------------  --------
PI   WO 2003059877       A2     20030724    WO 2002-US40920        20021219
     WO 2003059877       A3     20031211
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW:  GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2002367022       A1     20030730    AU 2002-367022         20021219
     US 20070269832      A1     20071122    US 2004-872754         20040621
PRAI US 2001-342955P     P      20011221
     WO 2002-US40920     W      20021219
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS   MARPAT 139:113655
AB   The invention provides novel serine protease affinity labels
     L-A-X-NHCH(R')C(:O)CH2Cl (L = label; A = bond or linker; X = absent,
     amino acid, peptide; R' = H, (substituted)C1-6-alkyl) or salts
     thereof, as well as compns. comprising such compds. or salts.  The composition
     of the amino acid side-chain (R') along with the amino acid or amino acid
     sequence (peptide) of the X component of the affinity label affect the
     target selectivity of the labeled affinity ligand.  Utilization of
     cell-permeable, enzyme-selective, labeled affinity ligands provides a
     precise mechanism for evaluating the current and future status of cell
     populations.  Thus, the induction of proteinases in camptothecin-treated
     HL-60 cells was observed by fluorescence microscopy after addition of serine
     proteinase affinity inhibitors 5(6)-carboxyfluoresceinyl-L-
     phenylalanylchloromethyl ketone (FFCK) and
     5(6)-carboxyfluoresceinyl-L-leucylchloromethyl ketone (FLCK) and caspase
     affinity inhibitor 5(6)-carboxyfluoresceinyl-L-
     valylalanylaspartylfluoromethyl ketone (FAM-VAD-FMK).
RE.CNT  2     THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d 111 kwic

L11  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2011 ACS on STN
TI   Fluorescent serine protease affinity labeling agents and methods for
```

determining apoptotic state of cells

AB The invention provides novel serine protease affinity labels L-A-X-NHCH(R')C(:O)CH2Cl (L = label; A = bond or linker; X = absent, amino acid, peptide; R' = H, (substituted)C1-6-alkyl) or salts thereof, as well as compns. comprising such compds. or salts. The composition of the. . . acid side-chain (R') along with the amino acid or amino acid sequence (peptide) of the X component of the affinity label affect the target selectivity of the labeled affinity ligand. Utilization of cell-permeable, enzyme-selective, labeled affinity ligands provides a precise mechanism for evaluating the current and future status. . .

=>